Healthcare
Harmony Biosciences Holdings, Inc. (HRMY)
Data as of July 17, 2026
Environment story
Harmony Biosciences discloses no Scope 1, 2, or 3 greenhouse-gas emissions data, net-zero targets, renewable-energy commitments, or environmental controversies in the 10-K filing. As a pharmaceutical company with no manufacturing operations (all outsourced to third-party CDMOs), direct operational carbon footprint is minimal. However, absence of environmental disclosure and no stated climate commitments result in deductions. No evidence of greenwashing detected, as company makes no environmental claims to scrutinize. Lack of data transparency prevents full environmental scoring.
Criticisms on file
No material criticisms on file for this pillar.
Disclosed initiatives
No disclosed initiatives on file for this pillar.
Social story
Harmony Biosciences provides no disclosed data on CEO-to-median-worker pay ratio, workforce diversity (gender/ethnicity), turnover rates, labor-union relations, or supply-chain human-rights audits in the 10-K filing. Company contracted manufacturing via CDMOs (Patheon, Corden Pharma, etc.) raises potential supply-chain governance questions, but no documented labor disputes, strikes, or union-suppression activities are evident in available filings. No civil-rights audits, diversity programs, or pay-equity commitments are disclosed. Absence of social-impact transparency and diversity metrics results in moderate deductions.
Criticisms on file
No material criticisms on file for this pillar.
Disclosed initiatives
-
Orphan Drug Designation for Rare DiseasesCompany's focus on rare neurological diseases (narcolepsy, PWS, DM1, Dravet Syndrome, Lennox-Gastaut Syndrome, Fragile X Syndrome) reflects commitment to underserved patient populations with limited treatment options.Addresses unmet medical needs in rare-disease communities; narcolepsy market ~$3.1B in 2025; PWS affects 15,000-20,000 US patients.
Governance story
Harmony Biosciences discloses no dual-class share structure in the 10-K; standard single-class common stock is inferred. Board independence percentage not explicitly stated in provided excerpts, preventing full assessment. Risk factor disclosure notes that 'directors, officers and principal stockholders beneficially own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval,' suggesting concentrated ownership but no explicit supermajority founder voting structure identified. No evidence of active lobbying to weaken climate or consumer-protection regulations; no material SEC consent decrees, antitrust, or privacy fines disclosed. Company is entirely dependent on Bioprojet licensing agreements for core IP; termination risk is a stated material risk but no current breach or litigation is evident.
Criticisms on file
No material criticisms on file for this pillar.
Disclosed initiatives
-
Intellectual Property Portfolio DevelopmentPatent protection for WAKIX and next-generation formulations (Pitolisant GR, Pitolisant HD) extending to mid-2040s; orphan-drug and pediatric-exclusivity strategies to protect market position.Long-term patent protection reduces competitive risk; pediatric exclusivity adds 6-month exclusivity period.
-
Compliance & cGMP OversightManufacturing partners (Corden Pharma, Patheon, etc.) subject to FDA inspection and cGMP compliance audits; formal audit program monitoring third-party compliance.Reduces regulatory risk from manufacturing defects or quality failures.
These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Harmony Biosciences Holdings, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Harmony Biosciences Holdings, Inc. in the app for interactive charts and portfolio building.
Browse Companies · Methodology · Terms of Service · Privacy Policy · Back to Missionomics